Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2026 17:54 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates...
March 17, 2026 17:02 ET | Source: Zymeworks Inc.

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR⍺)-targeting...
March 17, 2026 17:00 ET | Source: ArriVent BioPharma, Inc.

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor...
March 17, 2026 16:30 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces ADS Ratio Change

TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice...
March 17, 2026 16:30 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer Demonstration of Cyclin E1 protein overexpression as an...
March 16, 2026 16:04 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it...
March 16, 2026 16:02 ET | Source: Kyntra Bio

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and...
March 16, 2026 10:30 ET | Source: MarketsandMarkets Research Pvt. Ltd.

Cell Culture Market Projected to Reach USD 50.69 Billion by 2030 | MarketsandMarkets™

Delray Beach, FL, March 16, 2026 (GLOBE NEWSWIRE) -- The global cell culture market, valued at USD 27.92 billion in 2024, stood at USD 29.76 billion in 2025 and is projected to advance at a...
March 16, 2026 07:05 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted...
March 16, 2026 07:00 ET | Source: CytomX Therapeutics Inc.

CytomX’s Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - -...